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INHIBITION OF HISTONE DEACETYLASE
AS A TREATMENT FOR CARDIAC
HYPERTROPHY
The present invention claims benefit of priority to and is
a continuation of U.S. Ser. No. 10/256,221, filed Sep. 26,
2002, now issued as U.S. Pat. No. 6,706,686, which claims
priority to U.S. Provisional Ser. Nos. 60/325,311, filed Sep.
27, 2001, and 60/334/041, filed Oct. 31, 2001, the entire
contents of which are hereby incorporated by reference
without reservation.
The government owns rights in the present invention
pursuant to grant number NIH RO1 HL61544 from the
National Institutes of Health.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of
developmental biology and molecular biology. More
particularly, it concerns gene regulation and cellular physi-
ology in cardiomyocytes. Specifically, the invention relates
to the use of HDAC inhibitors to treat cardiac hypertrophy
and heart failure.
2. Description of Related Art
Cardiac hypertrophy in responseto an increased workload
imposed on the heart is a fundamental adaptive mechanism.
It is a specialized process reflecting a quantitative increase
in cell size and mass (rather than cell number) as the result
of any or a combination of neural, endocrine or mechanical
stimuli. Hypertension, another factor involved in cardiac
hypertrophy, is a frequent precursor of congestive heart
failure. When heart failure occurs, the left ventricle usually
is hypertrophied and dilated and indices of systolic function,
such as ejection fraction, are reduced. Clearly, the cardiac
hypertrophic response is a complex syndrome and the elu-
cidation of the pathways leading to cardiac hypertrophy will
be beneficial in the treatment of heart disease resulting from
a various stimuli.
A family of transcription factors, the myocyte enhancer
factor-2 family (MEF2), are involved in cardiac hypertro-
phy. For example, a variety of stimuli can elevate intracel-
lular calcium,resulting in a cascadeof intracellular signaling
systems or pathways, including calcineurin, CAM kinases,
PKC and MAP kinases. All of these signals activate MEF2
and result in cardiac hypertrophy. However, it is still not
completely understood how the various signal systems exert
their effects on MEF2 and modulate its hypertrophic signal-
ing. It is known that certain histone deacetylase proteins,
HDAC 4, HDAC 5, HDAC 7, HDAC9, and HDAC 10,are
involved in modulating MEF2activity.
Eleven different HDACs have been cloned from verte-
brate organisms. All share homologyin the catalytic region.
Histone acetylases and deacetylases play a major role in the
control of gene expression. The balance between activities
of histone acetylases, usually called acetyl transferases
(HATs), and deacetylases (HDACS) determinesthe level of
histone acetylation. Consequently, acetylated histones cause
relaxation of chromatin and activation of gene transcription,
whereas deacetylated chromatin is generally transcription-
ally inactive. In a previous report, the inventors’ laboratory
demonstrated that HDAC 4 and 5 dimerize with MEF2 and
repress the transcriptional activity of MEF2 and,further, that
this interaction requires the presence of the N-terminus of
the HDAC 4 and 5 proteins. McKinseyet al. (2000a,b).
In a distinct context, recent research has also highlighted
the important role of HDACs in cancer biology. In fact,
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various inhibitors of HDACsare beingtested for their ability
to induce cellular differentiation and/or apoptosis in cancer
cells. Marks et al. (2000). Such inhibitors include suberoy-
lanilide hydroxamic acid (SAHA) (Butler et al., 2000;
Marks et al., 2001); m-carboxycinnamic acid bis-
hydroxamide (Coffey et al., 2001); and pyroxamide (Butler
et al., 2001). These studies have been summarized as indi-
cating “that the hydroxamic acid-based HPCs,in particular
SAHAand pyroxamide—are potent inhibitors of HDAC in
vitro and in vivo and induce growtharrest, differentiation, or
apoptotic cell death of transformed cells . . . [and thus] are
lead compounds among the family of hydroxamic acid-
based HPCs and are currently in phase I clinical trials.”
Markset al. (2000). To date, no reports on the effects of
HDACinhibitors on muscle cell hypertrophy and response
to stress have been reported.
SUMMARYOF THE INVENTION
Thus, in accordance with the present invention, there is
provided a methodof treating pathologic cardiac hypertro-
phy and heart failure comprising (a) identifying a patient
having cardiac hypertrophy; and (b) administering to the
patient a histone deacetylase inhibitor. Administering may
comprise intravenous, oral, transdermal, sustained release,
suppository, or sublingual administration. The method may
further comprise administering a second therapeutic
regimen,such as a beta blocker, an iontrope, diuretic, ACE-I,
AIlI antagonist or Ca**-blocker. The second therapeutic
regimen may be administered at the same timeas the histone
deacetylase inhibitor, or either before or after the histone
deacetylase inhibitor. The treatment may improve one or
more symptoms of cardiac failure such as providing
increased exercise capacity, increased blood ejection
volume, left ventricular end diastolic pressure, pulmonary
capillary wedge pressure, cardiac output, cardiac index,
pulmonaryartery pressures,left ventricular end systolic and
diastolic dimensions, left and nght ventricular wall stress,
wall tension and wall thickness, quality of life, disease-
related morbidity and mortality.
In yet another embodiment, there is provided a method of
preventing pathologic cardiac hypertrophy and heart failure
comprising (a) identifying a patient at risk of developing
cardiac hypertrophy; and (b) administering to the patient a
histone deacetylase inhibitor. Administration may comprise
intravenous, oral, transdermal, sustained release,
suppository, or sublingual administration. The patientat risk
may exhibit one or more of long standing uncontrolled
hypertension, uncorrected valvular disease, chronic angina
and/or recent myocardial infarction.
In accordance with the preceding embodiments, the his-
tone deacetylase inhibitor may be any molecule that effects
a reduction in the activity of a histone deacetylase. This
includes proteins, peptides, DNA molecules (including
antisense), RNA molecules (including RNAi and antisense)
and small molecules. The small molecules include, but are
not limited to, trichostatin A, trapoxin B, MS 275-27,
m-carboxycinnamic acid bis-hydroxamide, depudecin,
oxamflatin, apicidin, suberoylanilide hydroxamic acid,
Scriptaid, pyroxamide, 2-amino-8-oxo-9,10-epoxy-
decanoyl, 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-
propenamide and FR901228. Additionally, the following
references describe histone deacetylase inhibitors which
may be selected for use in the current invention: AU
9,013,101; AU 9,013,201; AU 9,013,401; AU 6,794,700; EP
1,233,958; EP 1,208,086; EP 1,174,438; EP 1,173,562; EP
1,170,008; EP 1,123,111; JP 2001/348340; U.S. 2002/
103192; U.S. 2002/65282; U.S. 2002/61860; WO 02/51842;
US 6,946,441 B2
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WO 02/50285; WO 02/46144; WO 02/46129; WO
02/30879; WO 02/26703; WO 02/26696; WO 01/70675;
WO 01/42437; WO 01/38322; WO 01/18045; WO
01/14581; Furumaiet al. (2002); Hinnebuschet al. (2002);
Maiet al. (2002); Vigushin et al. (2002); Gottlicher et al.
(2001); Jung (2001); Komatsuet al. (2001); Suet al. (2000).
In still another embodiment, there is provided a method of
identifying inhibitors of cardiac hypertrophy comprising (a)
providing a histone deacetylase inhibitor; (b) treating a
myocyte with the histone deacetylase inhibitor; and (c)
measuring the expression of one or more cardiac hypertro-
phy parameters, wherein a changein the one or more cardiac
hypertrophy parameters, as compared to one or more cardiac
hypertrophy parameters in a myocyte not treated with the
histone deacetylase inhibitor, identifies the histone deacety-
lase inhibitor as an inhibitor of cardiac hypertrophy. The
myocyte may be subjected to a stimulus that triggers a
hypertrophic response in the one or more cardiac hypertro-
phy parameters, such as expression of a transgeneortreat-
ment with a drug.
The one or more cardiac hypertrophy parameters may
comprise the expression level of one or more target genes in
the myocyte, wherein the expression level of the one or more
target genes is indicative of cardiac hypertrophy. The one or
moretarget genes may be selected from the group consisting
of ANF, a-MyHC, B-MyHC, a-skeletal actin, SERCA,
cytochromeoxidase subunit VIII, mouse T-complex protein,
insulin growth factor binding protein, Tau-microtubule-
associated protein, ubiquitin carboxyl-terminal hydrolase,
Thy-1 cell-surface glycoprotein, or MyHCclass I antigen.
The expression level may be measured using a reporter
protein coding region operably linked to a target gene
promoter, such as luciferase, f-gal or green fluorescent
protein. The expression level may be measured using
hybridization of a nucleic acid probe to a target mRNA or
amplified nucleic acid product.
The one or more cardiac hypertrophy parameters also may
comprise one or more aspects of cellular morphology, such
as sarcomere assembly, cell size, or cell contractility. The
myocyte may be an isolated myocyte, or comprised in
isolated intact tissue. The myocyte also may be a
cardiomyocyte, and may be located in vivo in a functioning
intact heart muscle, such as functioning intact heart muscle
that is subjected to a stimulus that triggers a hypertrophic
response in one or more cardiac hypertrophy parameters.
The stimulus may be aortic banding, rapid cardiac pacing,
induced myocardial infarction, or transgene expression. The
one or more cardiac hypertrophy parameters comprisesright
ventricle ejection fraction, left ventricle ejection fraction,
ventricular wall thickness, heart weight/body weightratio,
or cardiac weight normalization measurement. The one or
more cardiac hypertrophy parameters also may comprise
total protein synthesis.
In still yet another embodiment, there is provided a
method of identifying inhibitors of cardiac hypertrophy
comprising (a) providing at least one class I and oneclass II
histone deacetylase; (b) contacting the histone deacetylases
with a candidate inhibitor substance; and (c) measuring the
activity of the histone deacetylases, wherein a greater
decrease in class I histone deacetylase activity than class II
histone deacetylase activity identifies the candidate inhibitor
substance as an inhibitor of cardiac hypertrophy. The histone
deacetylases may be purified away from whole cells or
located in an intact cell. The cell may be a myocyte, such as
a cardiomyocyte. Measuring HDACactivity may comprise
measuring release of a labeled acetyl group from a histone.
The label may be a radiolabel, a fluorescent label or a
chromophore.
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Theclass I histone deacetylase may be HDAC1, HDAC2,
HDAC3, or HDAC 8. The class II histone deacetylase may
be HDAC4, HDAC5, HDAC6, HDAC7, HDAC9,or HDAC
10. The activity of more than oneclass I histone deacetylase
may be measured. The activity of more than one class II
histone deacetylase may be measured. The activity of more
than oneclass I histone deacetylase and more than one class
II histone deacetylase may be measured. The candidate
inhibitor substance may have inhibitory activity against at
least one class I histone deacetylase and have no activity
against at least one class II histone deacetylase. The candi-
date inhibitor substance may have inhibitory activity against
multiple class I histone deacetylases and have no activity
against multiple class II histone deacetylases. The candidate
inhibitor substance may have inhibitory activity against at
least one class I histone deacetylase that is at least two-fold
greater than its inhibitory activity against at least one class
II histone deacetylase. The candidate inhibitor substance
may have inhibitory activity against at least one class I
histone deacetylase that is at least five-fold greater than its
inhibitory activity against at least one class II histone
deacetylase.
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawings form part of the present specifi-
cation and are included to further demonstrate certain
aspects of the present invention. The invention maybebetter
understood by reference to one or more of these drawings in
combination with the detailed description of specific
embodiments presented herein.
FIGS. 1A-C. TSAalters agonist-induced generepression.
Cultured cardiac myocytes were treated with PE (20 umol/
L) or IL-1 (1 ng/mL)for 48 hrs. TSA (30 nmol/L) was added
30 min.prior to treatment with PE or IL-1. Myocyte-specific
mRNA expression (SERCA2a (FIG. 1A), a@MyHC (FIG.
1B), BMyHC (FIG. 1C) was assayed in 5 ug total RNA by
RNase protection assay. Mean data are from 4 cultures, and
are presented as % of control after normalization to GAPDH
signal.
FIGS. 2A-D.Over-expression of HDACsrepress muscle-
specific promoters. Cultured myocytes were transfected for
72 hrs. with expression vectors (2 ug per ~3x105 cells) for
Flag-tagged HDAC1,4,5 (orits backbone vector) and CAT
reporter (5 ug) constructs for SERCA (FIG. 2A), aMyHC
(FIG. 2B), BMyHC (FIGS. 2C and 2D) genes, plus SV40-
driven secreted alkaline phosphatase (SEAP 1 xg, Clontech).
TSA was used at 30 nmol/L, and added just after the
transfection. PE 22 (20 wmol/L) was added 24 hrs. later and
CATassays performed after an additional 48 hours. Mean
data are from n=3 different cultures, and are presented as %
of pCMVafter normalization to SEAP activity in the media.
Over-expression of HDAC was confirmed by Western blot
for Flag.
FIGS. 3A—D. HDACinhibitors block the activation of
ANFreporter by phenylphrine without cytotoxicity. Neona-
tal rat cardiomyocytes were co-transfected with a total of 1
ug of the mouse 3 kb ANF promoter fragment and CMV-Lac
Z plasmids. (FIG. 3A) The ANF promoter is minimally
active in unstimulated cardiomyocytes. The addition of
HDACinhibitors does not induce ANF promoteractivity.
Addition of phenylphrine activated the ANF promoter, but
co-treatment of cardiomyoyctes with phenylephrine and a
HDACinhibitor (TSA (85 nM), NaBut (5 mM), or HC-toxin
(5 ng/ml)) prevented the activation of the ANF promoter by
phenylphrine (100 uM). (FIG. 3B) Lac Z expression by the
constitutive promoter CMV. Treatment with HDACinhibi-
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tors augmented CMVactivity with and without phenyleph-
rine co-treatment. (FIGS. 3C and 3D) The graphs show the
measurements of adenylate kinase activity remains constant
in the medium after X hours of culturing cardiomyocytes in
the absence or presence of hypertrophic stimulants FBS, PE
or ET-1.
FIGS. 4A-C. HDACinhibitors prevent endogenous ANF
expression normally induced by hypertrophic agonists.
(FIG. 4A) Graph shows the summation of several dot blot
experiments (n=4). As in the transfection experiments, phe-
nylephrine (100 CM) induces ANFexpression over three-
fold. Treatment with HDACinhibitors (TSA 85 nM; sodium
butyrate, 5 mM; HC-toxin 5 ng.ml) blocks the accumulation
of ANF message. (FIGS. 4B and 4C) The graphs show a
reduction of the chemiluminent detection of ANF in the
culture medium with increasing concentrations of the
HDACinhibitors TSA (FIG. 4B) and sodium butyrate (FIG.
4C) when co-cultured with the hypertrophic stimulants FBS,
PE or ET-1.
FIGS. 5A-B. Treatment of cardiomyocytes with HDAC
inhibitors blocks the fetal gene program associated with
cardiomyocyte hypertrophy. (FIG. 5A) Graph showsfold
changes in aSK-actin expression by phenylephrine and the
lack of gene activation in TSA-treated samples. (FIG. 5B)
Graph showsthe fold changes of aMyHC and BMyHC RNA
expression. Phenylephrine treatment induces the activation
of BMyHC expression (fetal gene) in cardiomyocytes;
whereas, phenylephrine alone does not active the aMyHC
gene, the adult isoform. Treatment with TSA prevented the
activation of BMyHC but stimulated the expression of
aMyHC. The graphs represent three or more independent
experiments
FIG.6. The effects of TSAtreatment on the reorganization
of the sarcomeres and protein synthesis. Graphs of the
measurements of S6 ribosome protein in cardiomyocytes
shows that phenylephrine and serum increases protein syn-
thesis in cardiomyocytes. Treatment of cardiomyocytes with
TSA does not alter this increase after 6 hours (graphs on
left). The graphs on the right show the content of S6
ribosome protein in cardiomyocytes after 24 hours
co-treatment with PE and increasing concentrations of TSA
or with serum and increasing concentrations of TSA.
FIGS. 7A-B. TSA inducesthe activation of genesthat are
involved in cardiomyocyte differentiation. (FIG. 7A) Three
genes were up-regulated by phenylephrine and down-
regulated by TSA.(FIG. 7B) Four genes wereinactivated by
phenylephrine and activated by TSA (results from one
phenylephrine chip, two phenylephrine/TSAchips, and one
TSA chip.)
DESCRIPTION OF ILLUSTRATIVE
EMBODIMENTS
Heartfailure is one of the leading causes of morbidity and
mortality in the world. In the U-S. alone, estimates, indicate
that 3 million people are currently living with cardiomyopa-
thy and another 400,000 are diagnosed on a yearly basis.
Dilated cardiomyopathy (DCM), also referred to as “con-
gestive cardiomyopathy,” is the most common form of the
cardiomyopathies and has an estimated prevalence of nearly
40 per 100,000 individuals (Durandet al., 1995). Although
there are other causes of DCM,familiar dilated cardiomy-
opathy has been indicated as representing approximately
20% of “idiopathic” DCM.Approximately half of the DCM
cases are idiopathic, with the remainder being associated
with known disease processes. For example, serious myo-
cardial damage can result from certain drugs used in cancer
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chemotherapy (e.g., doxorubicin and daunoribucin). In
addition, many DCM patients are chronic alcoholics.
Fortunately, for these patients, the progression of myocardial
dysfunction may be stopped or reversed if alcohol consump-
tion is reduced or stopped early in the course of disease.
Peripartum cardiomyopathy is another idiopathic form of
DCM,asis disease associated with infectious sequelae. In
sum, cardiomyopathies, including DCM,are significant pub-
lic health problems.
As cardiomyopathy itself typically does not produce any
symptoms until the cardiac damage is severe enough to
produce heart failure, the symptomsof cardiomyopathy are
those associated with heart failure. These symptoms include
shortness of breath, fatigue with exertion, the inability to lie
flat without becoming short of breath (orthopnea), paroxys-
mal nocturnal dyspnea, enlarged cardiac dimensions, and/or
swelling in the lower legs. Patients also often present with
increased blood pressure, extra heart sounds, cardiac
murmurs, pulmonary and systemic emboli, chest pain, pul-
monary congestion, and palpitations. In addition, DCM
causes decreased ejection fractions (i.e., a measure of both
intrinsic systolic function and remodeling). The disease is
further characterized by ventricular dilation and grossly
impaired systolic function due to diminished myocardial
contractility, which results in dilated heart failure in many
patients. Affected hearts also undergo cell/chamber remod-
eling as a result of the myocyte/myocardial dysfunction,
which contributes to the “DCM phenotype.” As the disease
progresses, the symptoms progress as well. Patients with
dilated cardiomyopathy also have a greatly increased inci-
denceof life-threatening arrhythmias, including ventricular
tachycardia and ventricularfibrillation. In these patients, an
episode of syncope (dizziness) is regarded as a harbinger of
sudden death.
Diagnosis of dilated cardiomyopathy typically depends
upon the demonstration of enlarged heart chambers,particu-
larly enlarged ventricles. Enlargement is commonly observ-
able on chest X-rays, but is more accurately assessed using
echocardiograms. DCM is often difficult to distinguish from
acute myocarditis, valvular heart disease, coronary artery
disease, and hypertensive heart disease. Once the diagnosis
of dilated cardiomyopathy is made, every effort is made to
identify and treat potentially reversible causes and prevent
further heart damage. For example, coronary artery disease
and valvular heart disease must be ruled out. Anemia,
abnormaltachycardias, nutritional deficiencies, alcoholism,
thyroid disease and/or other problems need to be addressed
and controlled.
During attempts to identify and stabilize the underlying
cause of the cardiomyopathy, treatment is generally insti-
tuted in order to minimize the symptoms and optimize the
efficiency of the failing heart. Medication remains the main-
stay of treatment, although there are no specific treatments
for dilated cardiomyopathy other than those used in heart
failure cases in general. Transplant surgery is one option.
Indeed, dilated cardiomyopathy has been indicated as the
most common cause for cardiac transplantation in the U.S.
Non-pharmacological treatment is primarily used as an
adjunct to pharmacological treatment. One means of non-
pharmacological treatment involves reducing the sodium in
the diet. In addition, non-pharmacological treatment also
entails the elimination of certain precipitating drugs, includ-
ing negative inotropic agents (e.g., certain calcium channel
blockers and antiarrhythmic drugs like disopyramide), car-
diotoxins(e.g., amphetamines), and plasma volume expand-
ers (e.g., nonsteroidal anti-inflammatory agents and
glucocorticoids).
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Treatment with pharmacological agents represents the
primary mechanism for reducing or eliminating the mani-
festations of heart failure. Diuretics constitute the first line
of treatment for mild-to-moderate heart failure.
Unfortunately, many of the commonly used diuretics(e.g.,
the thiazides) have numerous adverse effects. For example,
certain diuretics may increase serum cholesterol and trig-
lycerides. Moreover, diuretics are generally ineffective for
patients suffering from severe heart failure.
If diuretics are ineffective, vasodilatory agents may be
used; the angiotensin converting (ACE) inhibitors (e.g.,
enalopril and lisinopril) not only provide symptomaticrelief,
they also have been reported to decrease mortality (Young et
al., 1989). Again, however, the ACE inhibitors are associ-
ated with adverse effects that result in their being contrain-
dicated in patients with certain disease states (e.g., renal
artery stenosis).
Similarly, inotropic agent therapy (i.e., a drug that
improvescardiac output by increasing the force of myocar-
dial muscle contraction) may also be indicated if the diuret-
ics do not result in adequate relief. The inotropic agent most
commonly used by ambulatory patients is digitalis.
However, it is associated with a panoply of adverse
reactions, including gastrointestinal problems and central
nervous system dysfunction.
Thus, the currently used pharmacological agents have
severe shortcomings in particular patient populations. The
availability of new, safe and effective agents would undoubt-
edly benefit patients who either cannot use the pharmaco-
logical modalities presently available, or who do not receive
adequate relief from those modalities. The prognosis for
patients with DCM is variable, and depends uponthe degree
of ventricular dysfunction, with the majority of deaths
occurring within five years of diagnosis.
I. The Present Invention
The inventors have shownpreviously that MEF2is acti-
vated by MAP kinase phosphorylation of three conserved
sites in its carboxy-terminalactivation domain (see, Katoh et
al 1998). CaMKsignaling also activates MEF2 by phos-
phorylating the class IT HDACs, which are expressed at high
levels in the adult heart where they can repress MEF2
activity. Upon phosphorylation, these HDACsbind to 14-3-
3, and dissociate from MEF2,with resulting translocation to
the nucleus and activation of MEF2-dependenttranscription.
Mutants of class II HDACs that cannot be phosphorylated
cannot detach from MEF2andirreversibly block expression
of MEF? target genes.
It has also been shown that an adenovirus encoding a
non-phosphorylatable mutant of HDAC 5 is capable of
preventing cardiomyocyte hypertrophy in vitro in response
to diverse signaling pathways (see, Lu et al., 2000). These
findings suggest that phosphorylation of these conserved
sites in class IT HDACsis an essential step for initiating
cardiac hypertrophy. Based on these finding, one might
expect that inhibition of HDACactivity by TSAwould result
in the induction of cardiac hypertrophy because of derepres-
sion of hypertrophic responsive genes. On the contrary, the
present inventors found instead that TSA actually prevents
cardiac hypertrophy. These unexpected findings suggest that
at least some HDACsare required for hypertrophy and that
inhibition of HDACcatalytic activity can prevent activation
of hypertrophic genes.
How can these apparently conflicting results be
explained? One model arguesthat class I and II HDACs may
control different sets of genes in cardiomyocytes. According
to this model, class IT HDACsinteract with and repress the
activity of transcription factors, such as MEF2, that are
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required for hypertrophy, which would explain why non-
phosphorylatable mutants of class IT HDACs block hyper-
trophy. In contrast, it is proposed that class I HDACs,
HDAC1 and HDAC3 in particular, suppress the expression
of anti-hypertrophic genes. Thus, exposure of cardiomyo-
cytes to TSA would result in derepression of these anti-
hypertrophic genes and a blockade of hypertrophy. This
model also predicts that the activity of such anti-
hypertrophic genes would be dominant overthe activity of
class II HDACs,since they too are repressed by TSA, which
would be expected to derepress the hypertrophic program.
In any event, and regardless of the precise molecular
basis, the present invention showsthat, surprisingly, HDAC
inhibitors are beneficial in the treatment of cardiac hyper-
trophy and heart failure.
II. Histone Deacetylase
Nucleosomes, the primary scaffold of chromatin folding,
are dynamic macromolecular structures, influencing chro-
matin solution conformations (Workman and Kingston,
1998). The nucleosomecore is made up of histoneproteins,
H2A, HB, H3 and H4. Histone acetylation causes nucleo-
somes and nucleosomal arrangements to behave with altered
biophysical properties. The balance between activities of
histone acetyl transferases (HAT) and deacetylases (HDAC)
determines the level of histone acetylation. Acetylated his-
tones cause relaxation of chromatin and activation of gene
transcription, whereas deacetylated chromatin generally is
transcriptionally inactive.
Eleven different HDACs have been cloned from verte-
brate organisms. The first three human HDACs identified
were HDAC 1, HDAC 2 and HDAC 3 (termedclass I human
HDACs), and HDAC 8 (Van den Wyngaertet al., 2000) has
been added to this list. Recently class II human HDACs,
HDAC 4, HDAC 5, HDAC 6, HDAC 7, HDAC9, and
HDAC10 (Kaoet al., 2000) have been cloned and identified
(Grozingeret al., 1999; Zhouet al. 2001; Tonget al., 2002).
Additionally, HDAC 11 has been identified but not yet
classified as either class I or class II (Gaoet al., 2002). All
share homologyin the catalytic region. HDACs4,5, 7, 9 and
10 however, have a unique amino-terminal extension not
found in other HDACs. This amino-terminal region contains
the MEF2-binding domain. HDACs 4, 5 and 7 have been
shown to be involved in the regulation of cardiac gene
expression and in particular embodiments, repressing MEF2
transcriptional activity. The exact mechanism in whichclass
Il HDAC’s repress MEF2 activity is not completely under-
stood. One possibility is that HDAC binding to MEF2
inhibits MEF2 transcriptional activity, either competitively
or by destabilizing the native, transcriptionally active MEF2
conformation. It also is possible that class I] HDAC’s
require dimerization with MEF2 to localize or position
HDAC in a proximity to histones for deacetylation to
proceed.
III. Deacetylase Inhibitors
A variety of inhibitors for histone deacetylase have been
identified. The proposed uses range widely, but primarily
focus on cancer therapy. Saunders et al. (1999); Jung etal.
(1997); Jung et al. (1999); Vigushinet al. (1999); Kim etal.
(1999); Kitazomo et al. (2001); Vigusin et al. (2001);
Hoffmannet al. (2001); Kramer et al. (2001); Massaet al.
(2001); Komatsu et al. (2001); Han et al. (2001). Such
therapy is the subject of an NIH sponsored PhaseI clinical
trial for solid tumors and non-Hodgkin’s lymphoma.
HDAC’s also increase transcription of transgenes, thus
constituting a possible adjunct to gene therapy. Yamanoetal.
(2000); Su et al. (2000).
HDACscan be inhibited through a variety of different
mechanisms—proteins, peptides, and nucleic acids
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(including antisense and RNAi molecules). Methods are
widely known to those of skill in the art for the cloning,
transfer and expression of genetic constructs, which include
viral and non-viral vectors, and liposomes. Viral vectors
include adenovirus, adeno-associated virus, retrovirus, vac-
cina virus and herpesvirus.
Also contemplated are small molecule inhibitors. Perhaps
the most widely known small molecule inhibitor of HDAC
function is Trichostatin A, a hydroxamic acid. It has been
shown to induce hyperacetylation and cause reversion of ras
transformed cells to normal morphology (Taunton et al.,
1996) and induces immunsuppression in a mouse model
(Takahashi et al., 1996). It is commercially available from
BIOMOLResearch Labs, Inc., Plymouth Meeting, Pa.
The following references, incorporated herein by
reference, all describe HDACinhibitors that may find use in
the present invention: AU 9,013,101; AU 9,013,201; AU
9,013,401; AU 6,794,700; EP 1,233,958; EP 1,208,086; EP
1,174,438; EP 1,173,562; EP 1,170,008; EP 1,123,111; JP
2001/348340; U.S. 2002/103192; U.S. 2002/65282; US.
2002/61860; WO 02/51842; WO 02/50285; WO 02/46144;
WO 02/46129; WO 02/30879; WO 02/26703; WO
02/26696; WO 01/70675; WO 01/42437;WO 01/38322;
WO 01/18045; WO 01/14581; Furumaiet al. (2002); Hin-
nebusch et al. (2002); Mai et al. (2002); Vigushin et al.
(2002); Gottlicher et al. (2001); Jung (2001); Komatsuetal.
(2001); Su et al. (2000).
Examples of some specific HDACinhibitors are shown in
Table 1.
 
TABLE1
Chemical
Inhibitor Compound Type Composition Organism
Trapoxin B porphyrin derivative C33H39N,0,  H. ambiens
MS-27-275 benzamide Cy,H9N,03
derivative
Scriptaid hydroxamic acid CygH,.N04
FR901228 cyclopeptide Cy4H35NyO.S2 C. violaceum
(#968)
Depudecin fungal metabolite C,H604 A,
brassiciola
Oxamflatin aromatic CygH,4N,0,8,
sulfonamide
Pyroxamide hydroxamic acid C13H29N303
(suberoyl-3-
aminopyridineamide
hydroxyamic acid)
2-amino-8-oxo- ketone Cy9H,;NO3
9,10-epoxy-
decanoyl (AEO)
3-(4-aroyl-1 H- propenamide C,H,,N,0;
pytrol-2-yl)-
N-hydroxy-2-
propenamide
Suberoylanilide hydroxamic acid C,4H2>N203
hydroxamic acid
m-Carboxycinnamic hydroxamic acid CypHy5N204
acid bis-
hydroxamide
Apicidin* cyclopeptide CyoH3gNs05 Fusarium
CHAP!1(trichostatin hydroxamic/ spp.
A+ trapoxin B) porphryin
derivatives
 
+cyclo(N-O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-
8-oxodecanoyl)
IV. Methods of Treating Cardiac Hypertrophy
A. Therapeutic Regimens
In one embodimentof the present invention, methods for
the treatment of cardiac hypertrophy utilizing HDAC inhibi-
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tors are provided. For the purposes of the present
application, treatment comprises reducing one or more of
the symptoms of cardiac hypertrophy, such as reduced
exercise capacity, reduced blood ejection volume, increased
left ventricular end diastolic pressure, increased pulmonary
capillary wedge pressure, reduced cardiac output, cardiac
index, increased pulmonary artery pressures, increased left
ventricular end systolic and diastolic dimensions, and
increased left ventricular wall stress, wall tension and wall
thickness-samefor right ventricle. In addition, use of HDAC
inhibitors may prevent cardiac hypertrophy and its associ-
ated symptoms from arising.
Treatment regimens would vary depending onthe clinical
situation. However, long term maintenance would appear to
be appropriate in most circumstances. It also may be desir-
able treat hypertrophy with HDACinhibitors intermittently,
such as within brief window during disease progression. At
present, testing indicates that the optimal dosage for an
HDACinhibitor will be the maximal dose before significant
toxicity occurs.
B. Combined Therapy
In another embodiment, it is envisioned to use an HDAC
inhibition in combination with other therapeutic modalities.
Thus, in addition to the therapies described above, one may
also provide to the patient more “standard” pharmaceutical
cardiac therapies. Examples of standard therapies include,
without limitation, so-called “beta blockers,” anti-
hypertensives, cardiotonics, anti-thrombotics, vasodilators,
hormone antagonists, iontropes, diuretics, endothelin
antagonists, calcium channel blockers, phosphodiesterase
inhibitors, ACE inhibitors, angiotensin type 2 antagonists
and cytokine blockers/inhibitors.
Combinations may be achieved by contacting cardiac
cells with a single composition or pharmacological formu-
lation that includes both agents, or by contacting the cell
with two distinct compositions or formulations, at the same
time, wherein one composition includes the expression
construct and the other includes the agent. Alternatively, the
HDACinhibitor therapy may precede or follow administra-
tion of the other agent by intervals ranging from minutes to
weeks. In embodiments where the other agent and expres-
sion construct are applied separately to the cell, one would
generally ensure that a significant period of time did not
expire between the time of each delivery, such that the agent
and expression construct would still be able to exert an
advantageously combined effect on the cell. In such
instances,it is contemplated that one would typically contact
the cell with both modalities within about 12-24 hours of
each other and, more preferably, within about 6-12 hours of
each other, with a delay time of only about 12 hours being
most preferred. In somesituations, it may be desirable to
extend the time period for treatment significantly, however,
where several days (2, 3, 4, 5, 6 or 7) to several weeks (1,
2, 3, 4, 5, 6, 7 or 8) lapse between the respective adminis-
trations.
It also is conceivable that more than one administration of
either an HDACinhibitor, or the other agent will be desired.
In this regard, various combinations may be employed. By
wayofillustration, where the HDAC inhibitoris “A” and the
other agent is “B”, the following permutations based on 3
and 4 total administrations are exemplary:
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A/B/A B/A/B B/B/A A/A/B B/A/A A/B/B B/B/B/A B/B/A/B
12
A/A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B B/B/B/A
A/A/A/B B/A/A/A A/B/A/A A/A/B/A A/B/B/B B/A/B/B B/B/A/B
Other combinations are likewise contemplated.
C. Drug Formulations and Routes for Administration to 10
Patients
Where clinical applications are contemplated, pharma-
ceutical compositions will be prepared in a form appropriate
for the intended application. Generally, this will entail
preparing compositionsthat are essentially free of pyrogens,
as well as other impurities that could be harmful to humans
or animals.
Onewill generally desire to employ appropriate salts and
buffers to render delivery vectors stable and allow for uptake
by target cells. Buffers also will be employed when recom-
binant cells are introduced into a patient. Aqueous compo-
sitions of the present invention comprise an effective amount
of the vector or cells, dissolved or dispersed in a pharma-
ceutically acceptable carrier or aqueous medium. The phrase
“pharmaceutically or pharmacologically acceptable”refer to
molecular entities and compositions that do not produce
adverse, allergic, or other untoward reactions when admin-
istered to an animal or a human.As used herein, “pharma-
ceutically acceptable carrier” includes solvents, buffers,
solutions, dispersion media, coatings, antibacterial and anti-
fingal agents, isotonic and absorption delaying agents and
the like acceptable for use in formulating pharmaceuticals,
such as pharmaceuticals suitable for administration to
humans. The use of such media and agents for pharmaceu-
tically active substances is well known in the art. Except
insofar as any conventional media or agent is incompatible
with the active ingredients of the present invention, its use
in therapeutic compositions is contemplated. Supplementary
active ingredients also can be incorporated into the
compositions, provided they do not inactivate the vectors or
cells of the compositions.
The active compositions of the present invention may
include classic pharmaceutical preparations. Administration
of these compositions according to the present invention
may be via any commonroute so long as the targettissue is
available via that route. This includesoral, nasal, or buccal.
Alternatively, administration may be by intradermal,
subcutaneous, intramuscular, intraperitoneal or intravenous
injection. Such compositions would normally be adminis-
tered as pharmaceutically acceptable compositions, as
described supra.
The active compounds mayalso be administered parenter-
ally or intraperitoneally. By wayofillustration, solutions of
the active compounds as free base or pharmacologically
acceptable salts can be prepared in water suitably mixed
with a surfactant, such as hydroxypropylcellulose. Disper-
sions can also be prepared in glycerol, liquid polyethylene
glycols, and mixtures thereof and in oils. Under ordinary
conditions of storage and use, these preparations generally
contain a preservative to prevent the growth of microorgan-
isms.
The pharmaceutical forms suitable for injectable use
include, for example, sterile aqueous solutions or disper-
sions and sterile powders for the extemporaneous prepara-
tion ofsterile injectable solutions or dispersions. Generally,
these preparationsare sterile and fluid to the extent that easy
injectability exists. Preparations should be stable under the
conditions of manufacture and storage and should be pre-
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served against the contaminating action of microorganisms,
such as bacteria and fungi. Appropriate solvents or disper-
sion media may contain, for example, water, ethanol, polyol
(for example, glycerol, propylene glycol, and liquid poly-
ethylene glycol, and the like), suitable mixtures thereof, and
vegetable oils. The proper fluidity can be maintained, for
example, by the use of a coating, such as lecithin, by the
maintenance of the required particle size in the case of
dispersion and by the use of surfactants. The prevention of
the action of microorganisms can be brought about by
various antibacterial an antifingal agents, for example,
parabens, chlorobutanol, phenol, sorbic acid, thimerosal,
and the like; In many cases,it will be preferable to include
isotonic agents, for example, sugars or sodium chloride.
Prolonged absorption of the injectable compositions can be
brought about by the use in the compositions of agents
delaying absorption, for example, aluminum monostearate
and gelatin.
Sterile injectable solutions may be prepared by incorpo-
rating the active compounds in an appropriate amount into
a solvent along with any other ingredients (for example as
enumerated above) as desired, followed byfiltered steriliza-
tion. Generally, dispersions are prepared by incorporating
the varioussterilized active ingredients into a sterile vehicle
which contains the basic dispersion medium andthe desired
other ingredients, e.g., as enumerated above.In the case of
sterile powders for the preparation of sterile injectable
solutions, the preferred methods of preparation include
vacuum-drying and freeze-drying techniques which yield a
powder of the active ingredient(s) plus any additional
desired ingredient from a previously sterile-filtered solution
thereof.
For oral administration the polypeptides of the present
invention generally may be incorporated with excipients and
used in the form of non-ingestible mouthwashes and denti-
frices. A mouthwash may be prepared incorporating the
active ingredient in the required amount in an appropriate
solvent, such as a sodium borate solution (Dobell’s
Solution). Alternatively, the active ingredient may be incor-
porated into an antiseptic wash containing sodium borate,
glycerin and potassium bicarbonate. The active ingredient
may also be dispersed in dentifrices, including: gels, pastes,
powders and slurries. The active ingredient may be added in
a therapeutically effective amount to a paste dentifrice that
may include water, binders, abrasives, flavoring agents,
foaming agents, and humectants.
The compositions of the present invention generally may
be formulated in a neutral or salt form. Pharmaceutically-
acceptable salts include, for example, acid addition salts
(formed with the free amino groups of the protein) derived
from inorganicacids (e.g., hydrochloric or phosphoricacids,
or from organic acids (e.g., acetic, oxalic, tartaric, mandelic,
and the like. Salts formed with the free carboxyl groups of
the protein can also be derived from inorganic bases(e.g.,
sodium, potassium, ammonium, calcium, or ferric
hydroxides) or from organic bases (e.g., isopropylamine,
trimethylamine, histidine, procaine and the like.
Upon formulation, solutions are preferably administered
in a manner compatible with the dosage formulation and in
such amountas is therapeutically effective. The formulations
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may easily be administered in a variety of dosage forms such
as injectable solutions, drug release capsules and the like.
For parenteral administration in an aqueous solution, for
example, the solution generally is suitably buffered and the
liquid diluent first rendered isotonic for example with suf-
ficient saline or glucose. Such aqueous solutions may be
used, for example, for intravenous, intramuscular, subcuta-
neous and intraperitoneal administration. Preferably, sterile
aqueous media are employed as is knownto those of skill in
the art, particularly in light of the present disclosure. By way
of illustration, a single dose may be dissolved in 1 ml of
isotonic NaCl solution and either added to 1000 ml of
hypodermoclysis fluid or injected at the proposed site of
infusion, (see for example, “Remington’s Pharmaceutical
Sciences” 15th Edition, pages 1035-1038 and 1570-1580).
Somevariation in dosage will necessarily occur depending
on the condition of the subject being treated. The person
responsible for administration will, in any event, determine
the appropriate dose for the individual subject. Moreover,
for human administration, preparations should meetsterility,
pyrogenicity, general safety and purity standards as required
by FDA Office of Biologics standards.
V. Screening Methods
The present invention further comprises methods for
identifying inhibitors of HDACs that are useful in the
prevention or reversal of cardiac hypertrophy. These assays
may comprise random screening of large libraries of candi-
date substances; alternatively, the assays may be used to
focus on particular classes of compoundsselected with an
eye towards structural attributes that are believed to make
them morelikely to inhibit the function of HDACs.
To identify an HDAC inhibitor, one generally will deter-
mine the function of an HDACin the presence and absence
of the candidate substance. For example, a method generally
comprises:
(a) providing a candidate modulator;
(b) admixing the candidate modulator with an HDAC;
(c) measuring HDACactivity; and
(d) comparing the activity in step (c) with the activity in
the absence of the candidate modulator,
wherein a difference between the measured activities indi-
cates that the candidate modulatoris, indeed, a modulator of
the compound,cell or animal.
Assays also may be conducted in isolated cells or in
organisms. Typically, HDAC activity is measured by pro-
viding a histone with a labeled acetyl group and measuring
release of the label from the histone molecule.
It will, of course, be understood that all the screening
methods of the present invention are useful in themselves
notwithstanding the fact that effective candidates may not be
found. The invention provides methods for screening for
such candidates, not solely methods of finding them.
1. Modulators
As used herein the term “candidate substance” refers to
any molecule that may potentially inhibit HDACactivity.
The candidate substance may be a protein or fragment
thereof, a small molecule, or even a nucleic acid. It may
prove to be the case that the most useful pharmacological
compounds will be compoundsthat are structurally related
to known HDACinhibitors, listed elsewhere in this docu-
ment. Using lead compounds to help develop improved
compounds is knownas “rational drug design” and includes
not only comparisons with know inhibitors and activators,
but predictions relating to the structure of target molecules.
The goal of rational drug design is to produce structural
analogs of biologically active polypeptides or target com-
pounds. By creating such analogs,it is possible to fashion
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drugs, which are more active or stable than the natural
molecules, which have different susceptibility to alteration
or which mayaffect the function of various other molecules.
In one approach, one would generate a three-dimensional
structure for a target molecule, or a fragment thereof. This
could be accomplished by x-ray crystallography, computer
modeling or by a combination of both approaches.
It also is possible to use antibodies to ascertain the
structure of a target compound activator or inhibitor. In
principle, this approach yields a pharmacore upon which
subsequent drug design can be based.It is possible to bypass
protein crystallography altogether by generating anti-
idiotypic antibodies to a finctional, pharmacologically active
antibody. As a mirror image of a mirror image, the binding
site of anti-idiotype would be expected to be an analog of the
original antigen. The anti-idiotype could then be used to
identify and isolate peptides from banks of chemically- or
biologically-produced peptides. Selected peptides would
then serve as the pharmacore. Anti-idiotypes may be gen-
erated using the methods described herein for producing
antibodies, using an antibody as the antigen.
On the other hand, one may simply acquire, from various
commercial sources, small molecular libraries that are
believed to meet the basic criteria for useful drugs in an
effort to “brute force” the identification of useful com-
pounds. Screening of such libraries, including
combinatorially-generated libraries (e.g., peptide libraries),
is a rapid andefficient way to screen large numberofrelated
(and unrelated) compounds for activity. Combinatorial
approachesalso lend themselvesto rapid evolution of poten-
tial drugs by the creation of second, third and fourth gen-
eration compounds modeled ofactive, but otherwise unde-
sirable compounds.
Candidate compounds may include fragments or parts of
naturally-occurring compounds, or may be found asactive
combinations of known compounds, which are otherwise
inactive.It is proposed that compoundsisolated from natural
sources, such as animals, bacteria, fungi, plant sources,
including leaves and bark, and marine samples may be
assayed as candidates for the presence of potentially useful
pharmaceutical agents. It will be understood that the phar-
maceutical agents to be screened could also be derived or
synthesized from chemical compositions or man-made com-
pounds. Thus, it is understood that the candidate substance
identified by the present invention may be peptide,
polypeptide, polynucleotide, small molecule inhibitors or
any other compoundsthat may be designed throughrational
drug design starting from known inhibitors or stimulators.
Other suitable modulators include antisense molecules,
ribozymes, and antibodies (including single chain
antibodies), each of which would be specific for the target
molecule. Such compounds are described in greater detail
elsewhere in this document. For example, an antisense
molecule that boundto a translational or transcriptionalstart
site, or splice junctions, would be ideal candidate inhibitors.
In addition to the modulating compounds initially
identified, the inventors also contemplate that other steri-
cally similar compounds may be formulated to mimic the
key portions of the structure of the modulators. Such
compounds, which may include peptidomimetics of peptide
modulators, may be used in the same mannerasthe initial
modulators.
2. In vitro Assays
A quick, inexpensive and easy assay to run is an in vitro
assay. Such assays generally use isolated molecules, can be
run quickly and in large numbers, thereby increasing the
amount of information obtainable in a short period of time.
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Avariety of vessels may be used to run the assays, including
test tubes,plates, dishes and other surfaces such as dipsticks
or beads.
A technique for high throughput screening of compounds
is described in WO 84/03564. Large numbers of small
peptide test compoundsare synthesized on a solid substrate,
such as plastic pins or some other surface. Such peptides
could be rapidly screening for their ability to bind and inhibit
HDACs.
3. In cyto Assays
The present invention also contemplates the screening of
compounds for their ability to modulate HDACs in cells.
Various cell lines can be utilized for such screening assays,
including cells specifically engineered for this purpose.
4. In vivo Assays
In vivo assays involve the use of various animal models
of heart disease, including transgenic animals, that have
been engineered to have specific defects, or carry markers
that can be used to measure the ability of a candidate
substance to reach and effect different cells within the
organism. Dueto their size, ease of handling, and informa-
tion on their physiology and genetic make-up, mice are a
preferred embodiment, especially for transgenics. However,
other animals are suitable as well, including rats, rabbits,
hamsters, guinea pigs, gerbils, woodchucks, cats, dogs,
sheep, goats, pigs, cows, horses and monkeys (including
chimps, gibbons and baboons). Assays for inhibitors may be
conducted using an animal model derived from any of these
species.
Treatment of animals with test compounds will involve
the administration of the compound,in an appropriate form,
to the animal. Administration will be by any route that could
be utilized for clinical purposes. Determining the effective-
ness of a compound in vivo may involve a variety of
different criteria, including but not limited to. Also, measur-
ing toxicity and dose response can be performed in animals
in a more meaningful fashion than in in vitro or in cyto
assays.
VI. Definitions
As used herein, the term “heart failure” is broadly used to
mean any condition that reduces the ability of the heart to
pump blood. As a result, congestion and edema develop in
the tissues. Most frequently, heart failure is caused by
decreased contractility of the myocardium, resulting from
reduced coronary blood flow; however, many other factors
may result in heart failure, including damage to the heart
valves, vitamin deficiency, and primary cardiac muscle
disease. Though the precise physiological mechanisms of
heart failure are not entirely understood, heart failure is
generally believed to involve disorders in several cardiac
autonomic properties, including sympathetic,
parasympathetic, and baroreceptor responses. The phrase
“manifestations of heart failure” is used broadly to encom-
pass all of the sequelae associated with heart failure, such as
shortness of breath, pitting edema, an enlarged tenderliver,
engorged neck veins, pulmonaryrates and the like including
laboratory findings associated with heart failure.
The term “treatment” or grammatical equivalents encom-
passes the improvement and/orreversal of the symptoms of
heart failure (i.e., the ability of the heart to pump blood).
“Improvementin the physiologic function” of the heart may
be assessed using any of the measurements described herein
(e.g., measurement of ejection fraction, fractional
shortening, left ventricular internal dimension, heart rate,
etc.), as well as any effect upon the animal’s survival. In use
of animal models, the responseof treated transgenic animals
and untreated transgenic animals is compared using any of
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the assays described herein (in addition, treated and
untreated non-transgenic animals may be included as
controls). Acompound which causes an improvementin any
parameter associated with heart failure used in the screening
methodsof the instant invention may thereby be identified as
a therapeutic compound.
The term “dilated cardiomyopathy” refers to a type of
heart failure characterized by the presence of a symmetri-
cally dilated left ventricle with poor systolic contractile
function and, in addition, frequently involves the right
ventricle.
The term “compound” refers to any chemical entity,
pharmaceutical, drug, and the like that can be usedto treat
or prevent a disease, illness, sickness, or disorder of bodily
function. Compounds comprise both known and potential
therapeutic compounds. A compound can be determined to
be therapeutic by screening using the screening methods of
the present invention. A “known therapeutic compound”
refers to a therapeutic compoundthat has been shown(e.g.,
through animaltrials or prior experience with administration
to humans)to be effective in such treatment. In other words,
a knowntherapeutic compoundis notlimited to a compound
efficacious in the treatment of heart failure.
As used herein, the term “agonist” refers to molecules or
compounds which mimic the action of a “native” or “natu-
ral” compound. Agonists may be homologous to these
natural compounds in respect to conformation, charge or
other characteristics. Thus, agonists may be recognized by
receptors expressed on cell surfaces. This recognition may
result in physiologic and/or biochemical changes within the
cell, such that the cell reacts to the presence of the agonist
in the same mannerasif the natural compound waspresent.
Agonists may includeproteins, nucleic acids, carbohydrates,
or any other molecules that interact with a molecule,
receptor, and/or pathway ofinterest.
As used herein, the term “cardiac hypertrophy”refers to
the process in which adult cardiac myocytes respond to
stress through hypertrophic growth. Such growth is charac-
terized by cell size increases without cell division, assem-
bling of additional sarcomeres within the cell to maximize
force generation, and an activation of a fetal cardiac gene
program. Cardiac hypertrophy is often associated with
increased risk of morbidity and mortality, and thus studies
aimed at understanding the molecular mechanisms of car-
diac hypertrophy could have a significant impact on human
health.
As used herein, the terms “antagonist” and “inhibitor”
refer to molecules or compoundswhich inhibit the action of
acellular factor that may be involved in cardiac hypertrophy.
Antagonists may or may not be homologousto these natural
compounds in respect to conformation, charge or other
characteristics. Thus, antagonists may be recognized by the
sameor different receptors that are recognized by an agonist.
Antagonists may have allosteric effects which prevent the
action of an agonist. Alternatively, antagonists may prevent
the function of the agonist. In contrast to the agonists,
antagonistic compounds do not result in pathologic and/or
biochemical changes within the cell such that the cell reacts
to the presence of the antagonist in the same mannerasif the
cellular factor was present. Antagonists and inhibitors may
include proteins, nucleic acids, carbohydrates, or any other
molecules which bind or interact with a receptor, molecule,
and/or pathway ofinterest.
As used herein, the term “modulate” refers to a change or
an alteration in the biological activity. Modulation may be an
increase or a decrease in protein activity, a change in binding
characteristics, or any other change in the biological,
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finctional, or immunological properties associated with the
activity of a protein or other structure of interest. The term
“modulator” refers to any molecule or compound which is
capable of changing or altering biological activity as
described above.
The term “B-adrenergic receptor antagonist” refers to a
chemical compound or entity that 1s capable of blocking,
either partially or completely, the beta (6) type of adreno-
receptors (ie., receptors of the adrenergic system that
respond to catecholamines, especially norepinephrine).
Some f-adrenergic receptor antagonists exhibit a degree of
specificity for one receptor sybtype (generally B,); such
antagonists are termed “f,-specific adrenergic receptor
antagonists” and “§.,-specific adrenergic receptor antago-
nists.” The term B-adrenergic receptor antagonist” refers to
chemical compounds that are selective and non-selective
antagonists. Examples of f-adrenergic receptor antagonists
include, but are not limited to, acebutolol, atenolol,
butoxamine, carteolol, esmolol, labetolol, metoprolol,
nadolol, penbutolol, propanolol, and timolol. The use of
derivatives of known f-adrenergic receptor antagonists is
encompassed by the methods of the present invention.
Indeed any compound, which functionally behaves as a
B-adrenergic receptor antagonist is encompassed by the
methods of the present invention.
The terms “angiotensin-converting enzyme inhibitor” or
“ACEinhibitor” refer to a chemical compoundorentity that
is capable of inhibiting, either partially or completely, the
enzyme involved in the conversion of the relatively inactive
angiotensin I to the active angiotensin II in the rennin-
angiotensin system. In addition, the ACE inhibitors con-
comitantly inhibit the degradation of bradykinin, which
likely significantly enhances the antihypertensive effect of
the ACE inhibitors. Examples ofACEinhibitors include, but
are notlimited to, benazepril, captopril, enalopril, fosinopril,
lisinopril, quiapril and ramipril. The use of derivatives of
known ACEinhibitors is encompassed by the methodsofthe
present invention. Indeed any compound, which function-
ally behaves as an ACE inhibitor, is encompassed by the
methods of the present invention.
As used herein, the term “genotypes” refers to the actual
genetic make-up of an organism, while “phenotype”refers
to physicaltraits displayed by an individual. In addition, the
“phenotype” is the result of selective expression of the
genome(ie., it is an expression of the cell history andits
response to the extracellular environment). Indeed, the
human genomecontains an estimated 30,000-35,000 genes.
In each cell type, only a small (ie., 10-15%) fraction of these
genes are expressed.
VII. EXAMPLES
The following examples are included to further illustrate
various aspects of the invention. It should be appreciated by
those of skill in the art that the techniques disclosed in the
examples which follow represent techniques and/or compo-
sitions discovered by the inventor to function well in the
practice of the invention, and thus can be considered to
constitute preferred modesfor its practice. However, those
of skill in the art should, in light of the present disclosure,
appreciate that many changes can be made in the specific
embodiments which are disclosed andstill obtain a like or
similar result without departing from the spirit and scope of
the invention.
Example 1
Materials and Methods
Cell culture. Ventricular myocytes from one-day-old rats
were plated at low density in MEM with 5% calf serum, and
studied in serum-free MEM.Cultures were treated with PE
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(#P6126, Sigma-Aldrich Corp., St. Louis, Mo.), IL-1 (#501-
RL, R&D Systems, Minneapolis, Minn.), TSA (#GR-309,
BIOMOLResearch Laboratories, Inc., Plymouth Meeting,
Pa.) or their vehicles (ascorbic acid for PE; bovine serum
albumin for IL-1; dimethyl sulfoxide for TSA).
Detection of acetylated lysine residues. Total cell extract
wassubjected to Western blot analysis using antibodies from
Cell Signaling Technology (Beverly, Mass.) (acetylated
lysine antibody: #9441, acetylated histone H3 antibody at
Lysine 9: #9671, acetylated histone H3 antibody at Lysine
23: #9674, histone H3 antibody: #9712). Nuclear localiza-
tion of acetylated histone H3 was examined by inunun-
ostaining using the same antibodies.
Quantification of myocyte hypertrophy and myocyte-
specific mRNA expression. Growth of cultured myocytes
was quantified by content of radiolabeled protein after
continuous incubation with ‘+C-phenylalanine. For evalua-
tion of the myocyte gene program,total RNA wasextracted
from cells with TRIZol (GIBCO,Carlsbad, Calif.) and used
in RNase protection assay with probes for SERCA, a-/B-
MyHC, ANP, BNP, and cardiac a-actin. All samples also
included glyceraldehyde phosphate dehydrogenase
(GAPDH)as an internal control for RNA loading.
Transfection. Myocytes were transfected using calcium-
phosphate co-precipitation with cytomegalovirus promoter
driven Flag-tagged expression vectors for HDACs 1, 4, 5
and reporter plasmids carrying the rat promoters for SERCA
(3500 bp), aMyHC(2900 bp), or BMyHC (3300 bp) driving
expression 7 of the chroramphenicol acetyltransferase
(CAT) gene. Reporter expression was evaluated after 48
hours as described previously with corection for transfection
efficiency with SEAP (BD Biosciences Clontech, Palo Alto,
Calif.). Over-expression of HDACswas confirmed by West-
erm blot analyses using anti-Flag M2 antibody (Sigma-
Aldrich Corp. St. Louis, Mo.).
Results
TSA increases protein acetylation in cardiac myocytes.
Initial experiments were directed at confirming that TSA
was able to inhibit HDAC activity in cardiac myocytes,
reasoning that this should result in an overall increase in
protein acetylation. The degree of acetylation was deter-
mined using antibodies specific for acetylated lysine resi-
dues. Inventors showed by both Western blot and cellular
immunofluoresence analyses that exposure to TSA for 24
hours effectively increased acetylated lysine residues in a
numberof proteins and specifically those in Histone H3.
TSA enhances agonist-induced growth, but reverses
hypertrophy associated gene repression. Although TSA by
itself had no effect on myocyte growth, inventors found that
it enhanced the individual hypertrophic responses to both PE
and IL-1. Both hypertrophic stimuli down-regulated SERCA
(FIG. 1A) and aMyHC (FIG. 1B) expression and the
combined exposure to both agonists resulted in further
repression. In contrast, TSA increased the basal expression
of both SERCA2a and aMyHC mRNAs.TSApre-treatment
also resulted in a substantial reversal in the repression of
SERCAexpression by both hypertrophic stimuli. Notably,
although TSA resulted in a nearly complete reversal of the
PE effect on aMyHCexpression,this effect was less promi-
nent in the case of IL-1 treated (or co-treated) cells. Inven-
tors previously showed that co-treatment of cardiac myo-
cytes with both PE and IL-1 suppressed the usual PE
induction of aMyHCexpression by nearly 50%. It is intrigu-
ing that although TSA had no effects on either the basal
expression or PE-induction of this gene, it increased
aMyHC expression in the presence of IL-1 alone and
reversed the IL-1 effect in PE/IL-1 co-treated cells. A similar
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reversal was also seen with the sACT gene (Wang and Long,
unpublished data). Notably, TSA did notaffect gene expres-
sion of cardiac at-actin, ANP, or BNP under any hypertrophic
treatment condition (data not shown).
Over-expression of HDACrepressed promoteractivities
of myocyte-specific genes. In agreement with the studies of
mRNAexpression for these target genes, TSA also increased
the basal promoteractivities of both SERCA2 (FIG. 2A) and
aMyHC(FIG.2B) genes but not that of BMyHC (FIG. 2C).
Further, co-transfection of these constructs with expression
vectors for HDACs1 or 4 also decreased promoter activities
for both SERCA(FIG.2A) and aMyHC(FIG.2D)genes. In
contrast, however, HDACS5failed to inhibit the promoter
activities of either gene despite levels of expression similar
to that of the other isoforms (data not shown). Notably,all
three HDAC constructs were able to attenuate the
PE-induced increase in aMyHC promoter activity (FIG.
2D).
Example 2
Materials and Methods
Cardiomyocyte isolation. Hearts were harvested from
15-day timed-pregnant female Sprague-Dawley rats
(Harlan, Houston, Tex.). After mincing in phosphate-
buffered saline, cardiomyocytes were isolated from succes-
sive digestion fractions of 0.1% (w/v) Pancreatin (Sigma,St.
Louis, Mo.) solution. Fractions were collected; resuspended
in plating medium, pooled; and then plated for 2 hours to
separate fibroblasts from cardiomyocyte population. Sus-
pended cells were recollected and plated in 6-well dishes at
1x10° cells/well for transfection and immunofluorescence
experiments, and 2x10° cells in 10 cm dishes for RNA
analysis.
Transcription assay. Twenty-four hours after plating, cells
were transfected with total of 1 ug/ml for 5 hrs using
Lipofectamine Plus reagent (Invitrogen, Carlsbad, Calif.).
Transfected cells were incubated 24 hrs then treated for an
additional 24 hrs. Cells were lysed and their lysates assayed
with the Luciferase Assay System (Promega, Madison, Wis.)
for luminescence using Lucysoft 2 luminometer (Rosys
Anthos, New Castle, Del.).
Chemilumenescence. Neonatal cardiomyocytes were
seeded onto 96-well plates and treated for 72 hrs. The cells
were washed twice in 1xPBS, fixed in 4%
paraformaldehyde/1xPBS, and permeabilized with 0.1%
Triton-X100. After blocking, the cells were incubated 1 hr.
with 10 ug/ml monoclonal anti-ANF antibody (Biodesign).
The wells were washed twice with 1% BSA/1xPBSand then
incubated for 1 hr. with goat anti-mouse IgG-Fc-HRP
(Jackson Labs, location) at 1:1000 in 1xPBS/1% BSA.Cells
were washed twice with 1% BSA/1xPBS, twice with
1xPBS, then blotted dry. Luminol (Pierce, Rockford, IIL.)
was added and the chemiluminescence was detected in a
Fusion Plate Reader (Perkin Elmer/Packard).
Dot Blot analysis. Total RNA wasisolated from cardi-
omyocytes that were either untreated, treated with
phenylephrine, treated with TSA, or co-treated with phe-
nylephrine and TSA. One microgram of RNA wasblotted
onto Nitrocellulose (Bio-Rad, Hercules, Calif.) and hybrid-
ized at 50° C. for 14 hrs with end-labeled oligos. (ANF,
5'-aatgtgaccaagctgcgtgacacaccacaaggegcttaggatcttttgcgat
ctgctcaag-3, SEQ ID NO 1; a@SK actin5'-tggagcaaa
acagaatggctggctttaatgcttcaagttttccatttcctttccacaggg-3', SEQ
ID NO2; aMyHC, S5'cgaacgtttatgtttattgtggattggc-
cacagcgagest ctgctggagagg-3', SEQ ID NO 3; BMyHCS'-
gctttatictgcticcacctaaaggectgttgcaaagectccaggtictgaggecttc-
3', SEQ ID NO 4; GAPDHS'-ggaacatgtagaccatgtag
ttgaggtcaatgaag-3', SEQ ID NO 5). The blots were washed
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twice in 2xSSC/0.5% SDS solution and exposed to film
(Kodak, Rochester, N-Y.) or phosphoimager (Amersham
Bioscience, Sunnyvale, Calif.). The intensity of the hybrid-
ization of the probes was measured using ImageQuant©
(Amersham Bioscience, Sunnyvale, Calif.).
Immunostaining. Glass coverslips were coated with lami-
nin (Invitrogen, Carlsbad, Calif.) by solublizing laminin in
1xPBS (40 yg/ml), by dipping the coverslips in the solution
and by allowing them to air-dry. Cells were treated for 24
hrs, washed,fixed 10 min. with 3.7% formaldehyde, washed
with 1xPBS and permeabolized with 1xPBS containing 3%
BSA and 0.1% NP-40 (Sigma, St. Louis, Mo.). Primary
Antibodies were in 1xPBS containing 3% BSA and 0.1%
NP-40 for 30 min, then washed three times in 1xPBS. The
secondary FITC or TRITC antibodies (Vector Laboratories,
Inc., Burlingame, Calif.) were incubated (1:200) in same
buffer solution as the primary antibodies, then washed in
1xPBS,covered and subsequently visualized. Images were
captured using a digital camera (Hamamatsu Photonics,
Hamamatsu City, Japan).
Protein synthesis. Cardiomyocytes were incubated with
(1.0 wCi/ml; 172 Ci/mmolsp. activity) tritiated-leucine ICN
Biochemicals, Inc., Irvine, Calif.) in treated RPMI media
(Invitrogen, Carlsbad, Calif.). After 6 hrs incubation, the
cells were washed twice with 1xPBS,then incubated in 10%
TCAonice for 30 min. Afterwards, the cells were washed
twice with 5% TCA, once with water, and then lysed in 0.25
NaOH. Lysates were measured in one-sixth volume of
scintillation fluid by a scintillation counter (Beckman,
Fullerton, Calif.).
S6 Ribosomal protocol. After blocking, cells were incu-
bated in 1% BSA/1xPBScontaining 50 ug/ml anti-S6 pro-
tein (Cell Signaling, location) for 1 hr. After washing, the
cells were incubated with IgG-HRP (Jackson Labs,location)
at a 1:400 dilution. The cells were then washed twice in 1%
BSA/1xPBS, in 1xPBS,then blotted dry. Luminol (Pierce,
Rockford, Ill.) was added and the chemiluminescence was
detected in a Fusion reader (Perkin-Elmer/Packard).
Gene chip and analysis. RNA wasisolated using Trizol
(Invitrogen, Carlsbad, Calif.) from untreated,
phenylephrine-treated, TSA-treated, and phenylephine/TSA
co-treated rat neonatal cardiomyocytes. The RNAs were
prepared and hybridized on U34A chips (Affymetrix, Inc.,
Santa Clara, Calif.) according to Affymetrix protocols. The
intensity of hybridization was detected by and changes in
gene expression were determined and analyzed by Micro
Array Suite 5.0 (Affymetrix, Inc., Santa Clara, Calif.).
Results
Because histone deacetylases (HDACs) regulate gene
expression, the inventors analyzed whether HDAC inhibi-
tion would alter the expression of genes associated with
cardiac hypertrophy. Atrial natriuretic factor (ANF) is one
such gene, and its expression increases in presence of the
hypertrophic agonists. In order to determine whether HDAC
inhibition affects ANF gene activation, transfection experi-
ments were performed with the ANF promoter and trans-
fected cardiomyocytes were treated with phenylephrine and
several HDACinhibitors. Treatment of cardiomyocytes with
trichostatin (TSA), sodium butyrate (NaBut) or HC-toxin
(HC) did not activate the ANF promoter. The HDAC
inhibitors, however, did block the promoter’s activation by
phenylephrine treatment completely (FIG. 3A). This effect
was specific, because cardiomyocytes treated either with
each HDACinhibitor alone or together with phenylephrine
increased the transcriptional activity of the CMV-Lac Z
reporter (FIG. 3B), indicating that the action of these phar-
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macological agents was specific to the transcriptional con-
trol of ANF and not from general transcriptional inhibition.
Inventors then examined whetherincreasing doses of TSA
and sodium butyrate were cytotoxic to cultured cardiomyo-
cytes. To determine cell mortality, the release of adenylate
kinase from cardiomyocytes into the culture medium was
assayed. This assay is a known measurementfor the integ-
rity of the cell membrane: membranes become permeable in
dying cells causing the cells release adenylate kinase.
Increasing doses of TSA (up to 100 nM) and sodium
butyrate (up to 25 nM)did little to increase adenylate kinase
in the culture medium, indicating an absence of increased
cell death by TSA and sodium butyrate (FIGS. 3C & 3D). In
the single time-point experiments, 85 nM TSA or 5 mM
sodium butyrate were used, so these results indicate that
inactivation ofANFtranscriptionis a direct effect of HDAC
inhibition and not an indirect consequence of cytotoxicity by
the HDACinhibitors.
To determine whether endogenous gene expression par-
alleled the transfection results, the inventors looked at
endogenous RNAlevels ofANF from cardiomyocytes under
the various treatment conditions. RNA dot blot analysis of
phenylephrine-treated cardiomyocytes showed an approxi-
mate three-fold increase in the expression of ANF in
response to phenylephrine treatment; however, co-treatment
of phenylephrine-treated cells with the different HDAC
inhibitors (TSA, NaBut or HC-toxin) prevented the
phenylephrine-induced ANF response (FIG. 4A), in agree-
ment with the transfection results previously mentioned.
Prior data has shown that a low dose of TSA can induce
the ANF expression by acetylation of the ANF locus and by
inactivation of the transcription repressor, NRSE.To address
whether there is a dose-dependent effect of HDAC
inhibitors, inventors examined ANFexpressionafter treating
primary cardiomyocytes with increasing concentrations of
TSA (FIG. 4B) and sodium butyrate (FIG. 4C) in the
absence and presence of the hypertrophic stimulants serum
(FBS), phenylephrine (PE) or endothelin-1 (ET-1). At very
low doses (0.2 nM)of sodium butyrate (FIG. 4C), inventors
observed a near two-fold increase in ANF expression. There
was only a marginal increase increase with TSA (FIG. 4B).
However, the HDACinhibitors at all other concentrations
did not induce ANF production, and with increasing
concentrations, they countered the induction ofANF expres-
sion normally observed after treating cultured cardiomyo-
cytes with the growth stimulants FBS, PE and ET-1 (FIGS.
4B and C). The minimal concentrations that inhibited the
hypertrophic response of each growth stimulant were 40 nM
TSA and 5 mM sodium butyrate, which mimicked the
three-to-four-fold reduction of ANF in transcription
observed in the transfection and dot blot experiments. These
doses were well below the threshold of cytotoxicity.
Cardiac hypertrophy is associated with the reprogram-
ming of fetal genes in addition to ANF. The inventors wished
to determine whether other members of the fetal gene
cascade were affected by treatment of TSA. Quantitative
analysis of the fold change of a-sk expression and BMyHC,
in addition to ANF, showed that HDACinhibition resulted
in the suppression of other genes activated by the hyper-
trophic stimulant, phenylephrine (FIGS. 5A and B).
Furthermore, in addition to down-regulating the fetal myo-
sin chain isoform (BMyHC) isoform, TSA treatment of
cardiac myocytes induced the expression of aMyHC,the
adult myosin heavy chain isoform normally reduced in
hypertrophic cardiomyocytes (FIG. 5B). These data taken
together indicate that HDAC inhibition suppressesthe tran-
scriptional reprogramming of the gene cascade associated
with cardiomyocyte hypertrophy.
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Staining for ANF protein showed that cardiomyocytes
treated with phenylephrine or serum induced a perinuclear
accumulation of ANF protein compared to unstimulated
cells (data not shown). Cardiomyocytes treated with TSA
lacked accumulation ofANFprotein and the addition of TSA
to cardiomyocytes treated either with phenylephrine or with
serum dramatically reduced ANF protein accumulation.
Immunocytochemical staining for a-actinin showed that
HDAC inhibition antagonized the reorganization of the
sarcomere, another phenomenon associated with cardi-
omyocyte hypertrophy. Unstimulated cardiomyocytes main-
tained an amorphous shape with no apparent structural
organization of the sarcomere (a-actinin). Hypertrophic
agonists phenylephrine, serum, and ET-1 potently stimulated
the organization of the sarcomereas part of a highly ordered
cytoskeletal structure. Interestingly, TSA did affect cardi-
omyocyte morphology. Although TSA-treated cells did not
change size, they tended to acquire a “starred” appearance
by growing narrow extensions from the main body of the
cell. However, they lacked organization of the sarcomere.
The effect of TSA treatment was more dramatic in the
presence of growth stimulants, becauseit affected the hyper-
trophic morphology normally induced by phenylephrine,
serum or ET-1. TSA-treated cardiomyocytes lacked fully
organized sarcomeres.
The inventors then determined whether TSA antagonized
the increase in protein synthesis normally associated with
the hypertrophic response by assaying for changesin protein
synthesis and measuring the accumulation of the protein
contentof the ribosomal subunit, S6. Phenylephrine boosted
protein synthesis in the cardiac myocytes by two-fold after
6 hours of stimulation; however, co-culturing phenylephrine
with the HDAC inhibitors TSA and sodium butyrate had
little effect on the stimulation of protein synthesis normally
induced with phenylephrine (FIG. 6). Yet, by 24 hrs after
co-treatment, HDACinhibitors antagonized the protein syn-
thesis normally induced by PE or serum in a dose-dependent
manner (FIG. 6). This suggests that the prevention of the
organization of the sarcomere by HDAC inhibition is an
effect specific to transcription regulation.
Previous work has shown that TSA treatment of yeast
results in a change in gene expression in only a subset of
genes. If this is true for cardiomyocytes, then it is possible
that a limited number of genes are responsible for the
suppression of the hypertrophic phenotype. To identify these
genes, inventors assayed the expression of approximately
eight-thousand genes by gene chip array. Subsequent
graphic analysis of the assays of the expression between the
gene changes in the phenylephrine- and phenylephrine/
TSA-treated cells revealed that the majority of genes clus-
tered linearly. The majority of transcripts remained rela-
tively unchanged (less than a three-fold change in gene
expression) between the chip hybridized with RNA from
phenylephrine-treated cells and the chip hybridized with
RNAfrom phenylephrine/TSA-treated cells. This suggests
that the relative number of genes responsible for the sup-
pression of phenylephrine-induced cardiomyocyte growth
by TSA treatmentis low.
From the reduced number of genes whose expression
levels were altered by phenylephrine, TSA or their
combination, inventors identified seven genes that had a
consistent two-or-more-fold difference between phenyleph-
rine treatment and the TSA-treated groups: phenylephrine/
TSA and TSA. Three genes were up-regulated by phenyle-
phrine treatment and down-regulated by TSA: cytochrome
oxidase subunit VIII, mouse T-complex protein and insulin
growth factor binding protein-3 (FIG. 7A). Four genes
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down-regulated by phenylephrine and up-regulated by TSA
were big Tau-microtubule-associated protein, ubiquitin
carboxyl-terminal hydrolase, Thy-1 cell-surface glycopro-
tein and MyHCclassI antigen (FIG. 7B). Northern analysis
confirmed the expression results of the gene chip array (data
not shown).
All of the compositions and methods disclosed and
claimed herein can be made and executed without undue
experimentation in light of the present disclosure. While the
compositions and methods of this invention have been
described in terms of preferred embodiments, it will be
apparent to those of skill in the art that variations may be
applied to the compositions and methods,and in the steps or
in the sequence of steps of the methods described herein
without departing from the concept, spirit and scope of the
invention. More specifically, it will be apparent that certain
agents which are both chemically and physiologically
related may be substituted for the agents described herein
while the same or similar results would be achieved. All
such similar substitutes and modifications apparent to those
skilled in the art are deemedto be within the spirit, scope and
concept of the invention as defined by the appended claims.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 5
<210>
<211>
<212>
<213>
<220>
SEQ ID NO 1
LENGTH: 22
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE :
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-continued
 
<223> OTHER INFORMATION: Description of Artificial Sequence:
Primer
<400> SEQUENCE: 1
ecgaggccag ttgagatcag tc
<210> SEQ ID NO 2
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223>
Primer
<400> SEQUENCE: 2
aatgtgacca agctgcgtga cacaccacaa gggcttagga tcttttgcega tctgctcaag
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 3
LENGTH: 60
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
Primer
<400> SEQUENCE: 3
tggagcaaaa cagaatggct ggctttaatg cttcaagttt tccatttcct ttccacaggg
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 4
LENGTH: 52
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
Primer
<400> SEQUENCE: 4
cgaacgttta tgtttattgt ggattggcca cagcgagggt ctgctggaga gg
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 5
LENGTH: 57
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
Primer
<400> SEQUENCE: 5
gctttattct gcttccacct aaagggctgt tgqcaaaggct ccaggtctga gggcttc
OTHER INFORMATION: Description of Artificial Sequence:
OTHER INFORMATION: Description of Artificial Sequence:
OTHER INFORMATION: Description of Artificial Sequence:
OTHER INFORMATION: Description of Artificial Sequence:
Synthetic
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Synthetic
60
Synthetic
60
Synthetic
52
Synthetic
57
 
Whatis claimedis:
1. A method of treating heart failure comprising:
(a) identifying a patient having heart failure; and
(b) administering to said patient a histone deacetylase
inhibitor.
2. The method of claim 1, wherein said histone deacety-
lase inhibitor is selected from the group consisting of
trichostatin A, trapoxin B, MS 275-27, m-carboxycinnamic
acid bis-hydroxamide, depudecin, oxamfiatin, apicidin, sub-
eroylanilide hydroxamic acid, Scriptaid, pyroxamide,
2-amino-8-oxo-9,10-epoxy-decanoyl, 3-(4-aroyl-1H-pyrrol-
2-yl)-N-hydroxy-2-propenamide and FR901228.
3. The method of claim 1, wherein administering com-
prises intravenous administration of said histone deacetylase
inhibitor.
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4. The method of claim 1, wherein administering com-
prises oral, transdermal, sustained release, suppository, or
sublingual administration.
5. The method of claim 1, further comprising administer-
ing to said patient a second therapeutic regimen.
6. The method of claim 5 wherein said second therapeutic
regimen is selected from the group consisting of a beta
blocker, an iontrope, diuretic, ACE-I, AII antagonist, and
Ca**-blocker.
7. The method of claim 5, wherein said second therapeutic
regimen is administered at the same time as said histone
deacetylase inhibitor.
8. The method of claim 5, wherein said second therapeutic
regimen is administered either before or after said histone
deacetylase inhibitor.
9. The method of claim 1, wherein treating comprises
improving one or more symptomsof heart failure.
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10. The method of claim 9, wherein said one or more tricular end systolic and diastolic dimensions,left and right
symptoms comprises increased exercise capacity, increased ventricular wall stress, or wall tension, quality of life,
blood ejection volume, left ventricular end diastolic disease-related morbidity and mortality.
pressure, pulmonary capillary wedge pressure, cardiac
output, cardiac index, pulmonary artery pressures, left ven- ee oR
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